The short version of deamidation fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-16 and is reviewed periodically as new material appears.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized or solid form |
| Solubility | Sparingly soluble in water | May require buffer or pH adjustment |
| Typical storage temperature | 2–8 °C | Refrigerated; protect from light |
| Common analytical method | RP-HPLC | For purity and impurity profiling |
| Molecular weight | Approximately 4813 Da | For the peptide backbone; varies with counterions |
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Myositis Pulmonary involvement: Diffusion capacity < 70% of normal values Pulmonary hypertension Proliferative vascular lesions on lung biopsy Raynaud's phenomenon or esophageal hypomotility Swollen hands Anti-ENA antibody N 1:10,000 and anti-U1 RNP antibody positive and anti-Sm negative Minor criteria:
=== AI and data center regulation === In June 2026, Pritzker announced that the Illinois Department of Commerce and Economic Opportunity would suspend new state tax incentives for data center construction starting on July 1, 2026. The announcement came after the Illinois General Assembly failed to pass the POWER Act, which was legislation that would have required data centers to pay for and supply their own renewable energy, enter community benefits agreements, and report water usage. Pritzker took unilateral action after Speaker of Illinois House of Representatives Chris Welch said the pause did not have the House Democratic Caucus's support. Pritzker also said he opposed future "hyperscale" data centers in Illinois and rejected the idea of selling farmland to data center companies. On July 6, 2026, Pritzker signed into law Senate Bill 315, the Artificial Intelligence Safety Measures Act. The law regulates artificial intelligence (AI) with transparency and accountability rules for companies producing the largest AI models. The law was the first in the nation to require mandatory annual third-party audits and was opposed by TechNet, a coalition of technology sector executives, during debate in the Illinois General Assembly. The law was supported by artificial intelligence companies Anthropic and OpenAI and passed with bipartisan support, with only five state senators, all Republicans, voting against it.
In March 1999, the TF 2–505th INF deployed to Albania and forward-deployed along the Albania/Kosovo border in support of Operation Allied Force, NATO's bombing campaign against Serbian forces in the former Yugoslav Republic. In September 1999, TF 3–504th INF deployed in support of Operation Joint Guardian, replacing TF 2–505th INF. TF 3–504th INF was replaced in March 2000 by elements of the 101st Airborne Division. On 1 October 1999, the 1–508th ABCT (SETAF) made a combat jump in "Operation Rapid Guardian": 500-foot altitude jump near Pristina.
Santa Cruz) outlines the financially driven undertones of the company's actions. UCC had participated in decades of previous instances of "environmental negligence in every part of the world", directing its "responsibility… to its shareholders", and numerous dealings with local and international political and economic powers. The company's response to the Bhopal accident was what Rajan describes as a "campaign of erasure", meaning the transfer of liability and responsibility of the cause of the gas leak, the event itself, and the aftermath. Rajan then argues that this type of response is to be expected "according to [the] established cultural practice" within large corporations such as UCC. Since UCC absolved itself from the situation, the Indian government was the next institution that was looked to by the people of Bhopal, but they had also not prepared for such an event. The government's attempts at short and long-term plans failed in successfully aiding victims and instead "created an ecology of opportunity… built largely at the expense of the victims."
Sources: en.wikipedia.org
== Epidemiology == Numerical values regarding prevalence of uterine prolapse differ based on whether the epidemiologic study in question uses a physical exam or a symptom questionnaire to determine the presence of prolapse. Prevalence of pelvic organ prolapse was found to be consistently higher when physical exam was used (for uterine prolapse, this was 14.2% in one study and 3.8% in another) compared to a symptom-based determination in which the prevalence of any type of prolapse, including uterine prolapse, was 2.9% to 8% in the U.S. Using Women's Health Initiative data, the incidence of grades 1 to 3 uterine prolapse was approximately 1.5/100 women-years and progression of uterine prolapse was found to be about 1.9%.
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, California, by husband and wife team David and Alice Schwartz, both graduates of the University of California, Berkeley. Bio-Rad is based in Hercules, California, and has operations worldwide.
Gold nanoparticles improve the sensitivity of optical sensors in response to the change in the local refractive index. The angle of the incidence light for surface plasmon resonance, an interaction between light waves and conducting electrons in metal, changes when other substances are bounded to the metal surface. Because gold is very sensitive to its surroundings' dielectric constant, binding of an analyte significantly shifts the gold nanoparticle's SPR and therefore allows for more sensitive detection. Gold nanoparticle could also amplify the SPR signal. When the plasmon wave pass through the gold nanoparticle, the charge density in the wave and the electron I the gold interact and result in a higher energy response, referred to as electron coupling. When the analyte and bio-receptor both bind to the gold, the apparent mass of the analyte increases and therefore amplifies the signal. These properties had been used to build a DNA sensor with 1000-fold greater sensitivity than without the Au NP. Humidity sensors have also been built by altering the atom interspacing between molecules with humidity change, the interspacing change would also result in a change of the Au NP's LSPR.
Sources: en.wikipedia.org
RP-HPLC is widely used for purity and impurity profiling. Mass spectrometry confirms identity.
Typically refrigerated at 2–8 °C. Protect from light and avoid freezing.
Deamidation, oxidation, and aggregation products. SEC and ion-exchange chromatography are used.
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.